MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation

R. Sansone; D. Di Martino; E. Lanino; G. Dini; L. Massimo; G. P. Tonini

MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation

R. Sansone, D. Di Martino, E. Lanino, G. Dini, L. Massimo, G. P. Tonini

Istituto "Giannina Gaslini"

Research output: Contribution to journal › Article › peer-review

Abstract

From an extended series of neuroblastoma cases evaluated for MYCN amplification (MNA) at the 'G. Gaslini' Hospital 15 (4 with and 11 without MNA) underwent myeloablative therapy and bone marrow transplantation (MAT-ABMT). Such cases ranged in age at diagnosis from 13 months to 7 years and were followed up at least 8 months after MAT-ABMT. MNA was present in 2/10 cases dead for disease, in 0/1 cases alive with disease, and in 2/4 cases presently in complete clinical remission. This preliminary evidence would discourage to consider MNA as a marker capable of predicting the final outcome of patients with metastatic neuroblastoma.

Original language	English
Pages (from-to)	133-135
Number of pages	3
Journal	Bone Marrow Transplantation
Volume	7
Issue number	SUPPL. 3
Publication status	Published - 1991

ASJC Scopus subject areas

Hematology
Transplantation

Fingerprint Dive into the research topics of 'MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation'. Together they form a unique fingerprint.

Cite this

@article{108086d9b35d46cbbb8d72deb7ec04a7,

title = "MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation",

abstract = "From an extended series of neuroblastoma cases evaluated for MYCN amplification (MNA) at the 'G. Gaslini' Hospital 15 (4 with and 11 without MNA) underwent myeloablative therapy and bone marrow transplantation (MAT-ABMT). Such cases ranged in age at diagnosis from 13 months to 7 years and were followed up at least 8 months after MAT-ABMT. MNA was present in 2/10 cases dead for disease, in 0/1 cases alive with disease, and in 2/4 cases presently in complete clinical remission. This preliminary evidence would discourage to consider MNA as a marker capable of predicting the final outcome of patients with metastatic neuroblastoma.",

author = "R. Sansone and {Di Martino}, D. and E. Lanino and G. Dini and L. Massimo and Tonini, {G. P.}",

year = "1991",

language = "English",

volume = "7",

pages = "133--135",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "SUPPL. 3",

}

TY - JOUR

T1 - MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation

AU - Sansone, R.

AU - Di Martino, D.

AU - Lanino, E.

AU - Dini, G.

AU - Massimo, L.

AU - Tonini, G. P.

PY - 1991

Y1 - 1991

N2 - From an extended series of neuroblastoma cases evaluated for MYCN amplification (MNA) at the 'G. Gaslini' Hospital 15 (4 with and 11 without MNA) underwent myeloablative therapy and bone marrow transplantation (MAT-ABMT). Such cases ranged in age at diagnosis from 13 months to 7 years and were followed up at least 8 months after MAT-ABMT. MNA was present in 2/10 cases dead for disease, in 0/1 cases alive with disease, and in 2/4 cases presently in complete clinical remission. This preliminary evidence would discourage to consider MNA as a marker capable of predicting the final outcome of patients with metastatic neuroblastoma.

AB - From an extended series of neuroblastoma cases evaluated for MYCN amplification (MNA) at the 'G. Gaslini' Hospital 15 (4 with and 11 without MNA) underwent myeloablative therapy and bone marrow transplantation (MAT-ABMT). Such cases ranged in age at diagnosis from 13 months to 7 years and were followed up at least 8 months after MAT-ABMT. MNA was present in 2/10 cases dead for disease, in 0/1 cases alive with disease, and in 2/4 cases presently in complete clinical remission. This preliminary evidence would discourage to consider MNA as a marker capable of predicting the final outcome of patients with metastatic neuroblastoma.

UR - http://www.scopus.com/inward/record.url?scp=0025729861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025729861&partnerID=8YFLogxK

M3 - Article

C2 - 1855077

AN - SCOPUS:0025729861

VL - 7

SP - 133

EP - 135

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - SUPPL. 3

ER -

MYCN amplification does not affect survival of neuroblastoma patients treated with autologous bone marrow transplantation

Abstract

ASJC Scopus subject areas

Other files and links

Cite this